跳至主要内容
临床试验/NCT07554976
NCT07554976招募中不适用

Prospective, Multicenter, Randomized Controlled Study to Evaluate the Efficacy and Safety of a Suture-Mediated Closure System Following Percutaneous Common Femoral Vein Procedures

Suzhou Hengruihongyuan Medical Technology Co. LTD1 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2025年11月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
136
试验地点
1
主要终点
hemostasis success rate

研究概览

简要总结

The purpose of this study is to evaluate the effectiveness and safety of the suture-mediated closure system produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd. following Percutaneous Common Femoral Vein Procedures.

详细描述

Prospective, multi-center, randomized Comparative study using the Suture-mediated Closure System produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd.as an investigational device and the Perclose® ProGlide Suture-Mediated Closure System as a comparator. After going through the confirmation of inclusion/exclusion criteria with signed subjects, they will have a procedure either of the two devices. The subjects should follow designated physician's instructions accurately during the clinical trial period. There are about 4 times evaluations Including screening.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 18 to 80 years
  • Patients eligible for interventional catheter-based examination or treatment via common femoral artery puncture using sheaths sized 5F to 21F
  • Signed by the patient personally or by their legal representative on the Informed Consent Form

排除标准

  • Known pregnancy or lactation period;
  • Diameter of the common femoral artery on the puncture side < 5 mm;
  • Concurrent participation in another clinical research study;
  • Known allergy to any device component, and/or contraindications to contrast agents or anticoagulants;
  • Vascular injury at the access site;
  • Infection of the inguinal puncture site;
  • Morbid obesity (BMI ≥ 40 kg/m²);
  • Lower extremity vascular ultrasound for assessment of common femoral artery stenosis ≥50%;
  • Presence of femoral artery aneurysm, arteriovenous fistula, or pseudoaneurysm in the common femoral artery;
  • Previous use of clip-based vascular closure devices at the ipsilateral arterial access site;
  • Hematoma at the ipsilateral arterial access site;
  • Other conditions deemed unsuitable for participation in this clinical trial by the investigator.

研究组 & 干预措施

SPIDER

Experimental

干预措施: SPIDER (Device)

Perclose ProGlide

Active Comparator

干预措施: Perclose ProGlide (Device)

结局指标

主要结局

hemostasis success rate

时间窗: within 10 minutes post-suturing

次要结局

未报告次要终点

研究者

发起方
Suzhou Hengruihongyuan Medical Technology Co. LTD
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Suture-Mediated Closure System Following... | 临床试验